Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/899866/000144530512000363/alxn10k.htm
July 2021
July 2021
May 2021
May 2021
April 2021
March 2021
February 2021
February 2021
January 2021
December 2020
Exhibit 99.1
Contacts:
Alexion Pharmaceuticals, Inc. Irving Adler Sr. Director, Corporate Communications (203) 271-8210 |
Alexion Pharmaceuticals, Inc. Kimberly Diamond (Media) Director, Corporate Communications (203) 439-9600 |
Rx Communications (Investors) Rhonda Chiger (917) 322-2569 |
Alexion Reports Fourth Quarter and Full Year 2011 Results
- Soliris® (eculizumab) Net Product Sales Increased 45 Percent to $783 Million in 2011 -
- Continued Strong Uptake of Soliris by New PNH Patients; U.S. Launch in aHUS Begins -
- Pipeline Progresses with Five Compounds Targeting Severe and Ultra-Rare Disorders -
Fourth Quarter 2011 Financial Highlights:
| Q4 2011 net product sales increased 46 percent to $227.6 million, compared to $156.0 million in Q4 2010. |
| Q4 2011 GAAP net income increased 82 percent, to $48.2 million, or $0.25 per share, compared to Q4 2010 GAAP net income of $26.5 million, or $0.14 per share. |
| Q4 2011 non-GAAP net income increased 65 percent to $80.5 million, or $0.41 per share, compared to Q4 2010 non-GAAP net income of $48.6 million, or $0.26 per share. |
Full-Year 2011 Financial Highlights:
| 2011 net product sales increased 45 percent to $783.4 million, compared to $541.0 million in 2010. |
| 2011 GAAP net income increased 81 percent to $175.3 million, or $0.91 per share, compared to 2010 GAAP net income of $97.0 million, or $0.52 per share. |
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/899866/000144530512000363/alxn10k.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Alexion Pharmaceuticals, Inc..
Alexion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2012 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Alexion Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ALXN
CIK: 899866
Form Type: 10-K Annual Report
Accession Number: 0001445305-12-000363
Submitted to the SEC: Fri Feb 17 2012 5:29:44 PM EST
Accepted by the SEC: Fri Feb 17 2012
Period: Saturday, December 31, 2011
Industry: Pharmaceutical Preparations